14.11.2017 22:05
Bewerten
(0)

Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016

DRUCKEN

Innovus Pharmaceuticals, Inc. ("Innovus Pharma” or the "Company”) (OTCQB: INNV) today announced third quarter 2017 net revenue of $2.2 million compared to $1.9 million in net revenue for the same period in 2016. Net revenue for the nine months ended September 30, 2017 was $6.4 million compared to $3.1 million for the same period in 2016.

"We have increased our year-to-date product sales by over 105% when compared to the prior year without the potential added sales of FlutiCare™. This demonstrates our continued ability to generate significant sales growth from new and existing products through our Beyond Human® Sales and Marketing Platform,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. "Our first commercial batch of FlutiCare™ was received in October and we launched FlutiCare™ today which is one of the largest milestones for the Company. With the launch, we expect to continue the trend of increasing our net revenue while decreasing our loss from operations as we work towards our goal of profitability in 2018,” continued Dr. Damaj.

Financial highlights for the three months ended September 30, 2017 included:

  • Net revenue totaled $2.2 million for the three months ended September 30, 2017, compared to net revenue of $1.9 million for the three months ended September 30, 2016.
  • Net revenue during the third quarter of 2017 was impacted by the natural disasters in Florida and Texas as the Company was unable to advertise its products for a period of time in those regions as a result. These two states generate close to 15% of our total net revenue and have a population of approximately 17 million in our targeted product demographics*.
  • Total operating expense was $3.4 million for the three months ended September 30, 2017 or year over year decrease of $0.7 million or 16.7% when compared to the three months ended September 30, 2016.
  • Loss from operations decreased by $1.0 million or 45.8% to $1.2 million for the three months ended September 30, 2017 compared to the three months ended September 30, 2016.
  • Net loss totaled $1.3 million, or ($0.01) per common share, for the three months ended September 30, 2017 representing a 70.0% decrease year over year. The net loss included $0.5 million in non-cash expense related to the amortization of debt discounts, stock-based compensation and depreciation and amortization. Net loss for the three months ended September 30, 2016 totaled $4.4 million or ($0.04) per common share.
  • Cash used in operations decreased to approximately $577,000 for the three months ended September 30, 2017 compared to approximately $996,000 for the three months ended September 30, 2016.
  • Cash balance totaled $1.3 million at September 30, 2017.

Financial highlights for the nine months ended September 30, 2017 included:

  • Net revenue increased 105.8% to $6.4 million for the nine months ended September 30, 2017, compared to net revenue of $3.1 million for the nine months ended September 30, 2016.
  • Gross margin increased to 79.4% for the nine months ended September 30, 2017, higher than gross margin for the nine months ended September 30, 2016 which totaled 77.2%.
  • Total operating expense increased to $10.4 million and included $1.0 million in non-cash share-based compensation and $0.5 million in non-cash depreciation and amortization for the nine months ended September 30, 2017.
  • Net loss totaled $5.0 million, or ($0.03) per common share, for the nine months ended September 30, 2017. The net loss included a non-cash expense of $0.4 million for the loss on extinguishment of debt as a result of the prepayment of the remaining 2016 convertible debentures and settlement of notes payable. The net loss also included interest expense of $0.8 million, of which $0.7 million was non-cash and related to the amortization of debt discounts. Net loss for the nine months ended September 30, 2016 totaled $10.3 million or ($0.12) per common share.

Third quarter 2017 and recent developments:

  • Received our first commercial batch of 220,000 units of FlutiCare™ in October and launched FlutiCare™ in the U.S. in November 2017;
  • Moved corporate and company operations into a new 17,000 square-foot facility in San Diego, CA in November 2017 that will bring in-house the Company’s product fulfillment and inventory storage process. The move is designed to lower product fulfillment costs which will increase our gross product margins and decrease our loss from operations, as well as, provide the necessary office space to accommodate our expected revenue growth in 2018;
  • The combination of Apeaz™ cream for arthritis pain relief and ArthriVarx™, a supplement designed to maximize and support joint health, launched under the Beyond Human® Sales and Marketing Platform in July 2017;
  • Entered into an agreement with ACON Laboratories, Inc. to offer our customers a new FDA cleared urinary tract infection test in combination with their purchase of UriVarx™ and an FDA cleared glucose monitoring meter and test strips called the GlucoGorx™ Kit with their purchase of GlucoGorx™, the Company’s upcoming supplement for diabetic patients;
  • Received approval as a Natural Health Product by Health Canada for UriVarx™ for the indication to reduce symptoms of overactive bladder in September 2017 and for Vesele® to help improve nitric oxide production in symptoms of sexual dysfunction in October 2017;
  • Continued expansion of patent portfolio by receiving first Notification to Grant a Patent Right for Sensum+® in China in October 2017. Innovus Pharma has currently fourteen (14) issued patents and eight (8) patent applications covering several of its products and has licensed in an additional four (4) patents and five (5) patent applications from third parties covering additional products;
  • Expanded the exclusive license and distribution territory under our agreement with Densmore to Singapore and Vietnam in July 2017; and
  • Approval notification as a Class I medical device was received to commercialize Zestra® in Australia in July 2017 and in New Zealand in September 2017.

The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT today to discuss the financial results and recent business developments. To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers. Participant Elite Entry Number: 5606897. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally and reference Conference ID: 10113950. The replay will be available shortly after the end of the conference call.

   

Consolidated Statements of Operations

(Unaudited)

For the

Three Months Ended

September 30,

2017

       

2016

 
Net revenue:
Product sales, net $ 2,218,343 $ 1,882,129
License revenue   2,500     -  
Net revenue   2,220,843     1,882,129  
 
Operating expense:
Cost of product sales 480,076 331,227
Research and development 8,736 43,775
Sales and marketing 1,626,630 1,972,155
General and administrative   1,321,001     1,779,048  
Total operating expense   3,436,443     4,126,205  
 
Loss from operations   (1,215,600 )   (2,244,076 )
 
Other income and (expense):
Interest expense (104,276 ) (3,719,200 )
Loss on extinguishment of debt (89,341 ) -
Other income (expense), net (4,800 ) (37 )
Fair value adjustment for contingent consideration 69,305 186,813
Change in fair value of derivative liabilities   16,055     1,350,688  
Total other expense, net   (113,057 )   (2,181,736 )
 
Loss before provision for income taxes (1,328,657 ) (4,425,812 )
 
Provision for income taxes   -     -  
 
Net loss $ (1,328,657 ) $ (4,425,812 )
 
Net loss per share of common stock – basic and diluted $ (0.01 ) $ (0.04 )
 
Weighted average number of shares of common stock outstanding – basic and diluted   161,587,934       104,972,645  

 

 

 
 
 
(Unaudited)

For the

Nine Months Ended
September 30,
2017   2016  
Net revenue:
Product sales, net $ 6,426,790 $ 3,126,112
License revenue   10,000     1,000  
Net revenue   6,436,790     3,127,112  
 
Operating expense:
Cost of product sales 1,329,131 714,284
Research and development 26,982 47,667
Sales and marketing 4,869,717 2,257,166
General and administrative   4,207,899     4,012,357  
Total operating expense   10,433,729     7,031,474  
 
Loss from operations   (3,996,939 )   (3,904,362 )
 
Other income and (expense):
Interest expense (771,885 ) (5,970,450 )
Loss on extinguishment of debt (394,169 ) -
Other income (expense), net (5,622 ) 1,839
Fair value adjustment for contingent consideration 195,459 164,479
Change in fair value of derivative liabilities   (32,138 )   (632,627 )
 
Total other expense, net   (1,008,355 )   (6,436,759 )
 
Loss before provision for income taxes (5,005,294 ) (10,341,121 )
 
Provision for income taxes   3,200     -  
 
Net loss $ (5,008,494 ) $ (10,341,121 )
 
Net loss per share of common stock – basic and diluted $ (0.03 ) $ (0.12 )
 
Weighted average number of shares of common stock outstanding – basic and diluted   152,325,196       86,498,234  
 
 
       

Condensed Consolidated Balance Sheet Data

September 30, December 31,
2017 2016
(Unaudited) (1)
Assets
Cash $ 1,315,059 $ 829,933
Accounts receivable, net 27,526 33,575
Prepaid expense and other current assets 265,217 863,664
Inventories 640,055 599,856
Intangible assets & other non-current assets   5,429,548   5,900,350
Total assets $ 7,677,405 $ 8,227,378
 
Liabilities & Stockholders' Equity
Accounts payable and accrued expense $ 1,356,057 $ 1,210,050
Total accrued compensation 2,733,091 2,299,593
Deferred revenue and customer deposits - 11,000
Accrued interest payable 21,353 47,782
Total notes payable and non-convertible debenture, net of discount 780,056 681,127
Total derivative liabilities 74,151 483,744
Total contingent consideration 1,490,458 1,685,917
Convertible debentures, net of discount - 714,192
Total stockholders' equity   1,222,239   1,093,973
Total liabilities and stockholders’ equity $ 7,677,405 $ 8,227,378
 

(1) The Condensed Consolidated Balance Sheet Data has been derived from the audited consolidated financial statements as of that date.

 

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to be a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA”) products, men’s and women’s health supplements, related diagnostics and medical devices. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC, as well as related products.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

* Population data for Florida and Texas gathered from the 2010 Census Brief from the United States Census Bureau.

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its financial results, projected revenues, projected online subscribers and other customers, estimated markets for its products, and statements about achieving its other corporate and business development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Nachrichten zu Innovus Pharmaceuticals Inc

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Innovus Pharmaceuticals Inc

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen

Melden Sie sich jetzt an!

Roboter, Geräte mit künstlicher Intelligenz und automatisierte Maschinen sind bereits Teil unseres Lebens. Wie Anleger mit ETFs in diese Megatrends investieren können, erläutert Patrick Doser von BlackRock im "Webinar for professionals" am 27. November.
Hier zum "Webinar for professionals" anmelden!

Meistgelesene Innovus Pharmaceuticals News

Keine Nachrichten gefunden.
Weitere Innovus Pharmaceuticals News
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Payment-Trend: Der Vormarsch von digitalen Zahlungsabwicklern

Im neuen Anlegermagazin lesen Sie, warum vor allem asiatische Unternehmen beim Mobile-Payment eine wichtige Rolle spielen und welche Aktien vom mobilen Bezahlen profitieren könnten.
Anlegermagazin kostenlos erhalten

Innovus Pharmaceuticals Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX schließt kaum bewegt -- Dow im Feiertag -- thyssenkrupp übertrifft Erwartungen -- Investorenlegende Jim Rogers: "Bitcoin riecht nach Investment-Blase" -- MorphoSys, Software AG im Fokus

Commerzbank erwartet im DAX für 2017 eine Dividendensumme in Rekordhöhe. Rovio-Aktie bricht zweistellig ein: "Angry-Birds"-Erfinder enttäuscht mit Quartalsverlust. EZB verzichtete auf Enddatum für Anleihekäufe. CTS darf Konzertveranstalter Four Artists nicht übernehmen.

Top-Rankings

Die beliebtesten Weihnachtsgeschenke 2017
Welches Geschenk liegt am häufigsten unter dem Baum?
Diese Aktien hat George Soros im Depot
Welche ist die größte Aktienposition?
KW 46: Analysten-Flops der Woche
Diese Aktien stehen auf den Verkauflisten der Experten

Umfrage

Sind Sie in Bitcoins investiert?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Volkswagen (VW) AG Vz.766403
Deutsche Bank AG514000
AIXTRON SEA0WMPJ
Daimler AG710000
BYD Co. Ltd.A0M4W9
BP plc (British Petrol)850517
EVOTEC AG566480
Sabina Gold & Silver Corp.A0YC9U
Apple Inc.865985
Deutsche Telekom AG555750
GeelyA0CACX
CommerzbankCBK100
Infineon AG623100
Siemens AG723610
thyssenkrupp AG750000